tbuckley/cabot-search huggingface dataset:
IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors
Authors: R. Cimaz, M.-A. Cazalis, C. Reynaud, V. Gerloni, F. Zulian, M. Biggioggero, G. Martini, I. Pontikaki, F. Fantini, B. Mougin, P. Miossec
Journal: Annals of the Rheumatic Diseases (2007)

<b>Objective:</b> To investigate the genetic contribution of cytokine gene polymorphisms (interleukin 1 (IL1) and tumour necrosis factor α (TNFα)) on disease phenotype and on response to TNF-blocking agents in a population of patients with juvenile idiopathic arthritis (JIA). <b>Methods:</b> A cohort of 107 consecutive patients with JIA who were receiving treatment with anti-TNF agents was enrolled in this study. Analysis of genetic polymorphisms for IL1B +3954, IL1RA +2018, TNFα −238 and TNFα −308 was performed by enzyme-linked oligo sorbent assay, and compared with those obtained from 630 healthy Caucasians and 263 adult patients with rheumatoid arthritis. Relevant demographic, clinical and laboratory data were collected from clinical charts and entered into a customised database, and χ<sup>2</sup> analysis was performed to compare cytokine polymorphisms with disease type according to the International League of Associations for Rheumatology criteria, presence of uveitis, rheumatoid factor and anti-nuclear antibody positivity, erosive disease, frequency of adverse effects to anti-TNF and clinical response after 3 months. <b>Results:</b> The T/T genotype of the IL1B +3954 polymorphism was absent in patients with JIA and present in 5% of controls (p = 0.015). No significant correlation was found between the studied polymorphisms and clinical or laboratory variables considered. Clinical response to TNF inhibitors at 3 months was not associated with the genetic polymorphisms considered. <b>Conclusion:</b> In our cohort, the absence of the rare IL1B +3954 gene polymorphism was associated with JIA, but without specificity to particular disease phenotypes. The TNF and IL1 gene polymorphism studied did not seem to be associated with response to anti-TNF treatment.
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Authors: Mark Levis, Patrick Brown, B. Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel DeAngelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E. Karp, Donald Small
Journal: Blood (2006)
Troponin Levels and Mortality After Noncardiac Surgery
Authors: Robert D. Sanders
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predictors of patient and graft survival following liver transplantation for hepatitis C
Authors: Michael Charlton, Eric Seaberg, Russell Wiesner, James Everhart, Rowen Zetterman, John Lake, Katherine Detre, Jay Hoofnagle
Journal: Hepatology (1998)

End-stage liver disease secondary to hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the United States. Recurrence of HCV infection is nearly universal. We studied the patients enrolled in the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database to determine whether pretransplantation patient or donor variables could identify a subset of HCV-infected recipients with poor patient survival. Between April 15, 1990, and June 30, 1994, 166 HCV-infected and 509 HCV-negative patients underwent liver transplantation at the participating institutions. Median follow-up was 5.0 years for HCV-infected and 5.2 years for HCV-negative recipients. Pretransplantation donor and recipient characteristics, and patient and graft survival, were prospectively collected and compared. Cumulative patient survival for HCV-infected recipients was similar to that of recipients transplanted for chronic non-B-C hepatitis, or alcoholic and metabolic liver disease, better than that of patients transplanted for malignancy or hepatitis B (P = .02 and P = .003, respectively), and significantly worse than that of patients transplanted for cholestatic liver disease (P = .001). Recipients who had a pretransplantation HCV-RNA titer of > or = 1 x 10(6) vEq/mL had a cumulative 5-year survival of 57% versus 84% for those with HCV-RNA titers of < 1 x 10(6) vEq/mL (P = .0001). Patient and graft survival did not vary with recipient gender, HCV genotype, or induction immunosuppression regimen among the HCV-infected recipients. While long-term patient and graft survival following liver transplantation for end-stage liver disease secondary to HCV are generally comparable with that of most other indications, higher pretransplantation HCV-RNA titers are strongly associated with poor survival among HCV-infected recipients.
Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma
Authors: Donavan T. Cheng, Cynthia Ma, Jens Niewoehner, Martin Dahl, Angela Tsai, Jun Zhang, Waldemar Gonsiorek, Subbu Apparsundaram, Achal Pashine, Palanikumar Ravindran, Jimmy Jung, Julie Hang, John Allard, Hans Bitter, Catherine Tribouley, Satwant Narula, Stephen Wilson, Maria E. Fuentes
Journal: Journal of Allergy and Clinical Immunology (2013)
Atlas of Vascular Surgery
Authors: Theodore B. Massell
Journal: JAMA (1967)

In less than four years since the original publication of<i>Atlas of Vascular Surgery</i>, new developments in the field have made it desirable to bring out a second edition. The authors have added sections on the surgical management of complications of arterial prosthesis, embolectomy by the Fogarty balloon catheter, and emergency portacaval shunt. The chapter on arteriography has been revised but fails to describe the newer techniques of selective angiography of the aortic branches. Such subjects as renovascular hypertension, the resection of bleeding aortic aneurysm, and autogenous vein bypass for remoropopliteal occlusion, are treated in more detail and profusely illustrated. A paragraph or two is given to each of several other new developments in vascular surgery. From the new edition suggested forms for vascular examination and lists of special instruments for specific operative procedures have been omitted. The authors did not see fit also to delete the detailed descriptions of
SLP-65: A New Signaling Component in B Lymphocytes which Requires Expression of the Antigen Receptor for Phosphorylation
Authors: Jürgen Wienands, Jutta Schweikert, Bernd Wollscheid, Hassan Jumaa, Peter J. Nielsen, Michael Reth
Journal: The Journal of Experimental Medicine (1998)

The B cell antigen receptor (BCR) consists of the membrane-bound immunoglobulin (Ig) molecule as antigen-binding subunit and the Ig-α/Ig-β heterodimer as signaling subunit. BCR signal transduction involves activation of protein tyrosine kinases (PTKs) and phosphorylation of several proteins, only some of which have been identified. The phosphorylation of these proteins can be induced by exposure of B cells either to antigen or to the tyrosine phosphatase inhibitor pervanadate/H2O2. One of the earliest substrates in B cells is a 65-kD protein, which we identify here as a B cell adaptor protein. This protein, named SLP-65, is part of a signaling complex involving Grb-2 and Vav and shows homology to SLP-76, a signaling element of the T cell receptor. In pervanadate/H2O2-stimulated cells, SLP-65 becomes phosphorylated only upon expression of the BCR. These data suggest that SLP-65 is part of a BCR transducer complex.
Electrocardiographic appearance of old myocardial infarction in paced patients
Authors: Panos E. Vardas, George E. Kochiadakis, Michail D. Kaleboubas, Nikos E. Igoumenidis, Emmanuel I. Skalidis, Stavros I. Chrysostomakis, Michail I. Hamilos, Konstantinos E. Vardakis
Journal: Journal of the American College of Cardiology (2002)
Peritoneal dialysate fluid composition determines heat shock protein expression patterns in human mesothelial cells
Authors: Klaus Arbeiter, Bettina Bidmon, Michaela Endemann, Thorsten Onno Bender, Oliver Eickelberg, Dagmar Ruffingshofer, Thomas Mueller, Heinz Regele, Kurt Herkner, Christoph Aufricht
Journal: Kidney International (2001)
ST6Gal-I Protein Expression Is Upregulated in Human Epithelial Tumors and Correlates with Stem Cell Markers in Normal Tissues and Colon Cancer Cell Lines
Authors: Amanda F. Swindall, Angelina I. Londoño-Joshi, Matthew J. Schultz, Naomi Fineberg, Donald J. Buchsbaum, Susan L. Bellis
Journal: Cancer Research (2013)

Abstract The ST6Gal-I sialyltransferase adds an α2-6–linked sialic acid to the N-glycans of certain receptors. ST6Gal-I mRNA has been reported to be upregulated in human cancer, but a prior lack of antibodies has limited immunochemical analysis of the ST6Gal-I protein. Here, we show upregulated ST6Gal-I protein in several epithelial cancers, including many colon carcinomas. In normal colon, ST6Gal-I localized selectively to the base of crypts, where stem/progenitor cells are found, and the tissue staining patterns were similar to the established stem cell marker ALDH1. Similarly, ST6Gal-I expression was restricted to basal epidermal layers in skin, another stem/progenitor cell compartment. ST6Gal-I was highly expressed in induced pluripotent stem (iPS) cells, with no detectable expression in the fibroblasts from which iPS cells were derived. On the basis of these observations, we investigated further an association of ST6Gal-I with cancer stem cells (CSC). Selection of irinotecan resistance in colon carcinoma cells led to a greater proportion of CSCs compared with parental cells, as measured by the CSC markers CD133 and ALDH1 activity (Aldefluor). These chemoresistant cells exhibited a corresponding upregulation of ST6Gal-I expression. Conversely, short hairpin RNA (shRNA)-mediated attenuation of ST6Gal-I in colon carcinoma cells with elevated endogenous expression decreased the number of CD133/ALDH1-positive cells present in the cell population. Collectively, our results suggest that ST6Gal-I promotes tumorigenesis and may serve as a regulator of the stem cell phenotype in both normal and cancer cell populations. Cancer Res; 73(7); 2368–78. ©2012 AACR.
Hepatic Visualization after Radionuclide Venogram
Authors: KING-SUM SIU, MARC N. COEL
Journal: Clinical Nuclear Medicine (1984)

Ten days after an inferior vena caval clip was placed, left leg swelling developed in an 82-year-old white woman. Visualization of the liver, as well as the lungs, is thought to be due to pelvic collaterals shunting blood via the rectal (hemorrhoidal) veins, through the inferior mesenteric vein, and into the portal system (1).
Abstract 1880: Polymeric implants enhance bioavailability of curcumin by providing a continous (“24/7”) delivery system
Authors: Shyam S. Bansal, Hina Kausar, Farrukh Aqil, Manicka V. Vadhanam, Ramesh C. Gupta
Journal: Cancer Research (2010)

Abstract Curcumin, a potent natural chemopreventive agent, has shown significant anti-oxidant, anti-inflammatory, anti-proliferative, anti-metastatic, anti-angiogenic properties and is found to be effective against many ailments of inflammatory origin. However, it has elicited only limited success in various pre-clinical and clinical studies presumably due to its poor oral bioavailability. To increase the bioavailability of curcumin, we have developed novel polymeric implants using polycaprolactone (Mol. Wt. 65,000) (P-65) to achieve continuous (“24/7”) controlled delivery of curcumin directly into the systemic circulation. In this study, we investigated rate of curcumin release from the polymeric implants and tissue levels of curcumin in vivo by subcutaneously grafting 2-cm implants containing 20% (w/w) curcumin in female rats. Animals were euthanized at different intervals, and blood, different tissues and implants were collected. Measurement of the residual curcumin in the implants showed a burst release of 4.66 (11.7%) and 7.34 mg (18.4%) after 7 and 14 days, respectively, followed by a more controlled release. After 70 weeks nearly 76% curcumin was released. In another study, implants containing 10% curcumin showed similar rate of release from the implants. The in vivo release patterns mimicked the rate of release observed in vitro under ‘sink’ conditions. A solvent extraction and HPLC methodology was developed to measure tissue levels of curcumin. After 4 days, curcumin was detected at a level of 60 ± 20 ng/g liver and declined to almost constant levels of 12-14 ng/g tissue after 22 days. Analysis of CYP1A1 and GSTM levels as the biomarkers of curcumin efficacy showed a 13- and 16-fold induction in CYP1A1 levels after 4 and 7 days, respectively. GSTM levels were also found to be increased by 3- and 4-fold after 4 and 7 days, respectively. These studies showed that polymeric implants can deliver controlled amounts of curcumin systemically over an extended period of time increasing its bioavailability and elicit modulation of phase I and phase II enzymes (Supported from the USPHS grant CA-118114 and Agnes Brown Duggan Endowment.). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1880.
P291 COPD Discharge Bundles: The Exeter Experience 2011–12
Authors: DMG Halpin, P Batten, C Chamberlain
Journal: Thorax (2012)

<h3></h3> Bundles which facilitate standardised quality care have been used for over 10 years (1). Recently, discharge bundles for COPD have been proposed as a way of improving outcomes, including reducing readmission rates, for patients discharged from hospital. We introduced one based on a version developed in London (2) in 2011. It comprised 5 items addressing self management, inhaler technique (IT), smoking cessation advice (SA), pulmonary rehabilitation (PR), and follow up (FU). The bundle was completed by a respiratory nurse specialist (RNS) prior to discharge, they also planned to phone patients 24–72hrs post discharge. The bundle was used in 67 patients discharged Oct 2011-Mar 2012. In total 324 patients with COPD were discharged during this time. Five patients were discharged before the bundle had been completed. It was not used if patients were confused, lived out of area, or went to intermediate or palliative care. The mean age was 72 (range 49–91), CAT score 22.5, MRC 3.66, FEV1 33%, DOSE index 5.34. 58 (87%) received written advice, 17 (25%) were referred for or given SA, 65 (97%) had IT checked, 21 (31%) were referred for &amp; 19 (28% declined) PR, 58(89%) had FU requested. 39 (58%) were phoned within 72 hrs and 60 (92%) eventually. 77% of calls lasted 5 minutes or less. When contacted 37 (57%) of patients said they were better and 52 (80%) had no concerns. One patient was advised to restart steroids, 1 had a community matron visit arranged, 1 was readmitted &amp; 2 were given phone advice about coughs. One was constipated. Six of the 16 given SA were not smoking when phoned. 12 (18%) were readmitted within 30 days. This compares with a readmission rate of 27% in patients discharged during the same period who did not have the bundle completed. Discharge bundles and follow up calls ensured this group of elderly patients with severe or very severe COPD had important aspects of their management assessed prior to discharge and this appeared to reduce readmission rates. <h3>References</h3> Burger CD, Resar RK Mayo Clinic Proceedings. 2006; 81(6):849–850. Hopkinson NS, et al. Thorax 2012; 67:90–2.
Jiri Karel Lintner
Authors: B. Lintner
Journal: BMJ (2014)

Jiri Karel Lintner was born in Czechoslovakia. He was studying medicine at Brno University when the Nazis invaded in 1939 and closed the universities. He left his home country and made the hazardous journey to the Middle East to join the British Army. He fought at El Alamein and was decorated. In 1942 he was seconded to Beirut University to complete his studies. He then returned to active service as a doctor.

After the war he returned to Czechoslovakia with his first …
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
Authors: Brigette B.Y. Ma, Robert G. Bristow, John Kim, Lillian L. Siu
Journal: Journal of Clinical Oncology (2003)

Molecular targeted agents have been combined with radiotherapy (RT) in recent clinical trials in an effort to optimize the therapeutic index of RT. The appeal of this strategy lies in their potential target specificity and clinically acceptable toxicity.This article integrates the salient, published research findings into the underlying molecular mechanisms, preclinical efficacy, and clinical applicability of combining RT with molecular targeted agents. These agents include inhibitors of intracellular signal transduction molecules, modulators of apoptosis, inhibitors of cell cycle checkpoints control, antiangiogenic agents, and cyclo-oxygenase-2 inhibitors.Molecular targeted agents can have direct effects on the cytoprotective and cytotoxic pathways implicated in the cellular response to ionizing radiation (IR). These pathways involve cellular proliferation, DNA repair, cell cycle progression, nuclear transcription, tumor angiogenesis, and prostanoid-associated inflammation. These pathways can also converge to alter RT-induced apoptosis, terminal growth arrest, and reproductive cell death. Pharmacologic modulation of these pathways may potentially enhance tumor response to RT though inhibition of tumor repopulation, improvement of tumor oxygenation, redistribution during the cell cycle, and alteration of intrinsic tumor radiosensitivity.Combining RT and molecular targeted agents is a rational approach in the treatment of solid tumors. Translation of this approach from promising preclinical data to clinical trials is actively underway.
Thyroid Nodules as a Late Sequela of Radioactive Fallout
Authors: R. A. Conard, J. E. Rall, W. W. Sutow
Journal: New England Journal of Medicine (1966)

NODULES of the thyroid gland have been discovered during the past three years in a number of people of Rongelap Island who had been accidentally exposed to radioactive fallout in 1954. The accident was the result of an unpredicted shift in winds after the experimental detonation of a large thermonuclear device at Bikini in the Marshall Islands, which caused radioactive fallout to be deposited on 4 inhabited Marshall Islands to the east. Inhabitants of Rongelap Atoll, about 100 miles away, received the largest amount of fallout. The somatic effects of this radiation have been well documented in a number of . . .
Diagnosis in Gonorrhea
Authors: Ronald Schneider
Journal: JAMA (1978)

To the Editor.—  In his article  Treatment of Gonococcal Proctitis (239:735, 1978), Dr Fiumara suggested that patients be more carefully questioned with regard to their sexual preferences to treat gonococcal diseases appropriately. I would like to recommend an alternative diagnostic device. I routinely divide a single Thayer-Martin plate into the appropriate number of sections and culture all orifices without question. Only once did a patient object. I explained to the patient that as long as I tested (cultured) every place, I did not have to ask anyone any questions. The patient understood and readily cooperated. Not only does this spare the patient (and the physician) some embarrassment, but it also obviates any untruthfulness and resultant misdiagnoses.
Lipid-Lowering Therapy and Risk of Coronary Events
Authors: J. A. Blakely
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Estimating overdiagnosis in screening for abdominal aortic aneurysm: could a change in smoking habits and lowered aortic diameter tip the balance of screening towards harm?
Authors: M. Johansson, A. Hansson, J. Brodersen
Journal: BMJ (2015)

Clinical context—Abdominal aortic aneurysms (AAAs) are often asymptomatic until they rupture, when the death rate is greater than 80%. If diagnosed before rupture, AAA can be treated with surgery,  ...
Hormonal Regulation of Embryogenesis: The Formation of Mesoderm in<i>Xenopus laeuis</i>
Authors: PETER S. KLEIN, DOUGLAS A. MELTON
Journal: Endocrine Reviews (1994)

EMBRYONIC induction, the process wherein one cell instructs a responding cell to adopt a particular fate, bears striking parallels to a number of endocrine regulatory systems (1). In addition to utilizing similar intracellular signal transduction mechanisms, many of the extracellular signals used are the same. Regulation of metamorphosis in frogs by thyroid hormone is a classical example which has seen renewed interest recently, and activin, follistatin, fibroblast growth factor (FGF), and epidermal growth factor all appear to have roles in the early embryo. Embryonic induction bears other parallels to endocrine systems as well; for example, the responding cell is sensitive to very low levels of inducing signals. In addition, the type of response to a given signal is determined by the responding cell, by the type of receptors present, regulation of the intracellular signaling components, or activation of different downstream targets. Finally, the distinctions between endocrine, paracrine, and autocrine phenomena are critical to understanding inductive signaling; the question of how an inductive signal is propagated through the embryo remains an important and unsolved problem in modern embryology.